ESR1 and breast cancer: Luminal BCs have a favorable prognosis because the presence of the ERα dictates the clinical use of the endocrine therapy (ET) drugs (i.e., aromatase inhibitors, Tam and fulvestrant), which aim to eliminate ERα and/or its signaling from BC cells [1–5].